Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs

Journal of Pharmaceutical Sciences

Volumn 101, Issue 11, 2012, Pages 4327-4336

  Kulkarni, Rajesh ^a   Yumibe, Nathan ^a   Wang, Zhongyi ^a   Zhang, Xin ^a   Tang, Cheng Cai ^a   Ruterbories, Kenneth ^a   Cox, Amy ^a   McCain, Robyn ^c   Knipp, Gregory T ^b,c  

^a ELI LILLY AND COMPANY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Absorption; Bioavailability; Controlled release; Dissolution; In vitro in vivo correlation (IVIVC); Pharmacokinetics pharmacodynamics model; Physiological model

Indexed keywords

GLIPIZIDE; GLUCOSE; PLACEBO;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; GLUCOSE BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SWINE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84866399895     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23292     Document Type: Article

References (46)

1. Ritschel WA. 1989. Biopharmaceutic and pharmacokinetic aspects in the design of controlled release peroral drug delivery systems. Drug Dev Ind Pharm 15:1073-1103.
2. Qiu Y. 2009. Rational design of oral modified-release drug delivery systems. In Developing solid oral dosage forms: Pharmaceutical theory and practice; Qiu Y, Chen Y, Zhang GZ, Liu L, Porter W, Eds. 1st ed. Academic Press, Waltham, Massachusetts, pp 469-499.
3. Gray V, Kelly G, Xia M, Butler C, Thomas S, Mayock S. 2009. The science of USP 1 and 2 dissolution: Present challenges and future relevance. Pharm Res 26:1289-1302.
4. Skelly JP, Barr WH, Benet LZ, Doluisio JT, Goldberg AH, Levy G, Lowenthal DT, Robinson JR, Shah VP, Temple RJ, Yacobi A. 1987. Report of the workshop on controlled-release dosage forms: Issues and controversies. Pharm Res 4:75-77.
5. Guidance for industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. 1997. U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Accessed July 5, 2012, at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070239.pdf.
6. Kimura T, Higaki K. 2002. Gastrointestinal transit and drug absorption. Biol Pharm Bull 25:149-164.
7. Fadda HM, Sousa T, Carlsson AS, Abrahamsson B, Williams JG, Kumar D, Basit AW. 2010. Drug solubility in luminal fluids from different regions of the small and large intestine of humans. Mol Pharm 7:1527-1532.
8. Coupe AJ, Davis SS, Wilding IR. 1991. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 8:360-364.
9. Collins PJ, Horowitz M, Cook DJ, Harding PE, Shearman DJC. 1983. Gastric emptying in normal subjects-A reproducible technique using a single scintillation camera and computer system. Gut 24:1117-1125.
10. Charman WN, Porter CJH, Mithani S, Dressman JB. 1997. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci 86:269-282.
11. Podczeck F, Mitchell CL, Newton JM, Evans D, Short MB. 2007. The gastric emptying of food as measured by gamma-scintigraphy and electrical impedance tomography (EIT) and its influence on the gastric emptying of tablets of different dimensions. J Pharm Pharmacol 59(11):1527-1536.
12. McConnell EL, Fadda HM, Basit AW. 2008. Gut instincts: Explorations in intestinal physiology and drug delivery. Int J Pharm 364:213-226.
13. Karim A, Burns T, Janky D, Hurwitz A. 1985. Food-induced changes in theophylline absorption from controlled-release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption. Clin Pharmacol Ther 38:642-647.
14. Yu LX, Zhang H. 2004. Dissolution testing for solid oral drug products: Theoretical considerations. Am Pharm Rev 7:26-31.
15. Gao JG, Hussain MA, Motheram R, Gray DAB, Benedek IH, Fiske WD, Doll WJ, Sandefer E, Page RC, Digenis GA. 2007. Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). J Pharm Sci 96:2970-2977.
16. Donauer N, Löbenberg R. 2007. A mini review of scientific and pharmacopeial requirements for the disintegration test. Int J Pharm 345:2-8.
17. Curtis MJ. 2010. The RETHINK project: Impact of toxicity testing in the minipig as an alternative approach in regulatory toxicity testing. J Pharmacol Toxicol Methods 62(3):157-162.
18. Desso, JM, Williams, AL. 2008. Contrasting the gastrointestinal tracts of mammals: Factors that influence absorption. Ann Rep Med Chem 43:353-371.
19. De Zwart LL, Rompelberg CJM, Sips AJAM, Welink J, van Engelen JGM. 1999. Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics. RIVM report 623860010.
20. Kararli TT. 1995. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351-380.
21. Sjögren E, Bredberg U, Lennernäs H. 2012. The pharmacokinetics and hepatic disposition of repaglinide in pigs: Mechanistic modeling of metabolism and transport. Mol Pharm 9:823-841.
22. Thörn HA, Lundahl A, Schrickx JA, Dickinson PA, Lennernäs H. 2011. Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. Eur J Pharm Sci 43:89-98.
23. Lundahl A, Hedeland M, Bondesson U, Lennernäs H. 2011. In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. Drug Metab Dispos 39:847-857.
24. Matsson EM, Palm JE, Eriksson UG, Bottner P, Lundahl A, Knutson L, Lennernäs H. 2011. Effects of ketoconazole on the in vivo biotransformation and hepatobiliary transport of the thrombin inhibitor AZD0837 in pigs. Drug Metab Dispos 39:239-246.
25. Sjögren E, Bredberg U, Allard E, Arvidsson B, Bergquist J, Andersson TB, Lennernäs H. 2010. Hepatic disposition of ximelagatran and its metabolites in pig; prediction of the impact of membrane transporters through a simple disposition model. Pharm Res 27:597-607.
26. Fink-Gremmels J. 2008. Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. Eur J Pharmacol 585:502-509.
27. Köhn F, Sharifi AR, Taubert H, Malovrh S, Simianer H. 2007. Breeding for low body weight in Goettingen minipigs. J Anim Breed Genet 125:20-28.
28. Skaanild MT. 2006. Porcine cytochrome P450 and metabolism. Curr Pharm Des 12:1421-1427.
29. Skaanild MT, Friis C. 2000. Expression changes of CYP2A and CYP3A in microsomes from pig liver and cultured hepatocytes. Pharm Toxicol 87:174-178.
30. Souček P, Zuber R, Anzenbacherová E, Anzenbacher P, Guengerich FP. 2001. Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs. BMC Pharmacol 1:11-14.
31. Bader A, Hansen T, Kirchner G, Allmeling C, Haverich A, Borlak JT. 2000. Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. Br J Pharmacol 129:331-342.
32. Anzenbacher P, Souček P, Aanzenbacherová E, Gut I, Hrubý K, Svoboda Z, Květina J. 2008. Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples. Drug Metab Dispos 26:56-59.
33. DeGraw TR, Knipp G, Matthews D, Marchant-Forde J, Mann D, McCain R. 2009. Measuring induction of carbamazepine metabolism in pigs using automated blood sampling (Abstract #380). AAPS J 11(Suppl 1).
34. Rohde-Johnson C, DeGraw RT, Marchant-Forde J, Knipp GT, McCain RR, Matthews DL. 2009. ECG and pharmacokinetic assessment in the freely moving pig. 2009 Minipig Research Forum of North America, Lansdowne, Virginia:.
35. Petri N, Bergman E, Forsell P, Hedeland M, Bondesson U, Knutson L, Lennernäs H. 2006. First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab Dispos 34:1182-1189.
36. Sjödin E, Fritsch H, Eriksson U, Logren U, Nordgren A, Forsell P, Knutson L, Lennernäs H. 2008. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. Drug Metab Dispos 36:1519-1528.
37. Sköld C, Winiwarter S, Wernevik J, Bergström F, Engström L, Allen R, Box K, Comer J, Mole J, Hallberg A, Lennernäs H, Lundstedt T, Ungell A, Karlén A. 2006. Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies. J Med Chem 49:6660-6671.
38. Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS. 1979. Glipizide: A review of its pharmacological properties and therapeutic use. Drugs 18:329-353.
39. Gram LK, Rist GM, Lennernäs H, Steffansen B. 2009. Impact of carriers in oral absorption: Permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide. Eur J Pharm Sci 37:378-386.
40. Berelowitz M, Fischette C, Cefalu W, Schade D, Sutfin T, Kourides 1994. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 17:1460-1464.
41. Chung M, Kourides I, Canovatchel W, Sutfin T, Messig M, Chaiken RL. 2002. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. J Clin Pharmacol 42:651-657.
42. Marchant-Forde JN, Matthews DL, Poletto R, McCain RR, Mann DD, McGraw RT, Hampsch J, Peters S, Knipp GT, Kissinger CB. 2012. Plasma cortisol and noradrenalin concentrations in pigs: Automated sampling of freely moving pigs housed in the PigTurn® versus manually sampled and restrained pigs. Anim Welf 21:197-205.
43. The United States Pharmacopoeia and National Formulary USP 34 NF 29 USP Monographs Glipizide Tablets. 2011. The United States Pharmacopeial Convention, Inc., Rockville, Maryland, pp. 2972:2973.
44. Fassihi R, Jamzad S. 2006. Role of surfactant and pH on dissolution properties of fenofibrate and glipizide-A technical note. AAPS PharmSciTech 7:E1-E6.
45. Fassihi R, Jamzad S. 2006. Development of a controlled release low dose class II drug-Glipizide. Int J Pharm 312:24-32.
46. Sankalia JM, Sankalia MG, Mashru RC. 2008. Drug release and swelling kinetics of directly compressed glipizide sustained-release matrices: Establishment of level A IVIVC. J Control Release 129:49-58.